Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Anixa Biosciences (ANIX – Research Report) and keeping the price target at $10.00.
Jason McCarthy has given his Buy rating due to a combination of factors related to Anixa Biosciences’ innovative approaches in oncology. The company’s recent collaboration with VERDI Solutions for an AI-driven cancer vaccine platform is a significant development. This platform, which uses artificial intelligence to create personalized vaccines, has shown promise in real-world applications in Germany, suggesting potential for broader clinical success.
Additionally, Anixa’s ongoing efforts in developing a breast cancer vaccine targeting alpha-lactalbumin, particularly for triple-negative breast cancer, further strengthen its position in the biotechnology sector. The company’s strategic partnerships and funding arrangements, such as with the Cleveland Clinic, provide it with the resources to advance its programs. These factors, combined with a favorable valuation model, contribute to McCarthy’s optimistic outlook and Buy rating for Anixa Biosciences.
In another report released on March 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.
ANIX’s price has also changed slightly for the past six months – from $3.150 to $3.150, which is a 0% increase.